未知生产厂商
BI 1701963 (Boehringer Ingelheim) is a SOS1/pan-KRAS inhibitor currently being evaluated in phase I clinical trials in patients with advanced KRAS-mutated cancers.
BI 1701963 (Boehringer Ingelheim) is a SOS1/pan-KRAS inhibitor currently being evaluated in phase I clinical trials in patients with advanced KRAS-mutated cancers.
Small-molecule inhibitor that selectively binds to SOS1, blocking the protein–protein interaction with guanosine diphosphate–bound RAS (SOS1::KRAS interaction inhibitor).
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
